

## Finalisation of historical R&D tax claims

**17 December 2025**

Epiminder Limited (ASX:EPI) (**Epiminder** or the **Company**) refers to Section 10.12 of its IPO Prospectus dated 10 November 2025 which disclosed that the Company would reserve \$20 million of the IPO proceeds to pay a tax liability to the Australian Taxation Office (**ATO**) in respect of R&D tax offset claims in relation to the income years ended 30 June 2019 to 30 June 2024.

The Company today announces that it has received final notices of amended assessment from the ATO in relation to these matters requiring the Company to repay \$15,766,493 to the ATO by 19 December 2025. The Company confirms that payment of this amount discharges the Company's outstanding obligations to the ATO in respect of these matters. The balance of \$4,233,507 set aside from the IPO proceeds for these matters will be retained by the Company for working capital purposes.

### **Authorisation**

This announcement has been authorized for lodgement to the ASX by Epiminder's Board of Directors.

### **Investor & Media Enquiries**

Mark Grady  
0412 376 817  
mark@candradvisory.com

Stephen Dabkowski  
0419 880 486  
[steve@bluedot.net.au](mailto:steve@bluedot.net.au)

For any Company queries please contact Epiminder at [investors@epiminder.com](mailto:investors@epiminder.com)

+++

Follow Epiminder on [LinkedIn](#) and explore [Epiminder.com](https://www.epiminder.com) for more information.

### **About Minder**

Minder is a minimally invasive device for continuous monitoring of electrographic activity of the brain, providing epilepsy patients and their doctors with detailed data on brain activity over an extended period. Patients can wear the device as they go about their normal daily activities.

Minder's long-term monitoring of patients outside a controlled clinical environment provides clinicians with the data needed to remotely monitor and assess the patient's underlying condition, including the effectiveness of drug therapies and other interventions.

For personal use only

## About Epiminder

Founded in 2017 by Professor Mark Cook together with the Bionics Institute, St Vincent's Hospital, the University of Melbourne and Cochlear Limited, Epiminder is a medical device and information solutions company focused on developing diagnostic and treatment tools for epilepsy and other seizure disorders where continuous monitoring is required. Epiminder is headquartered in Melbourne, Australia and has offices in the United States.